Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term study of Givinostat in Duchenne muscular dystrophy
2017-000397-10Phase 3Active
- Sponsor
- Italfarmaco
- Start
- Jan 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of givinostat in Duchenne muscular dystrophy (DMD), sponsored by Italfarmaco. Primary endpoint: Safety and tolerability of long-term Givinostat treatment. Started Jan 2018; status: active.
02
Drugs
givinostat
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2017-000397-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000397-10.